Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

NEWTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. ALNA, a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Alexey Margolin, Ph.D., Allena's Chief Executive Officer, will present a company overview at the Jefferies 2018 Healthcare Conference on Wednesday, June 6, 2018 at 2:00 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Company's website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannahd@sternir.com